Citations

Mayo Clinic

Showing 10 of 108522 citations.

Procurement Trends, Indications, and Outcomes of Heart–Lung Transplantation in the Contemporary Era
Treffalls, John A. , Brennan, Zachary , Chen, Qiudong , Pennington, Kelly M. , Spencer, Philip J. , Villavicencio, Mauricio A. , Daly, Richard C. , Saddoughi, Sahar A. , Griffeth, Elaine M. , Chen, Qiudong , Pennington, Kelly , Spencer, Philip J , Bilgili, Ahmet , Sharaf, Omar M.

Clinical Transplantation | September 3, 2024 | Volume: 38 | Issue: 9 | Pages: No page available

10.1111/ctr.15447 | PMID 39225590 Get It

ABSTRACTBackgroundEvolving trends in organ procurement and technological innovation prompted an investigation into recent trends, indications, and outcomes following combined heart–lung transplantation (HLTx).MethodsThe United Network for Organ Sharing database was queried for all adult (≥18 years) HLTx performed between July 1, 2013 and June 30, 2023. Patients with previous transplants were excluded. The primary endpoint was the effect of donor, recipient, and transplantation characteristics on 1‐ and 5‐year survival. Secondary analyses included a comparison of HLTx at high‐ and low‐volume centers, an assessment of HLTx following donation after circulatory death (DCD), and an evaluation of HLTx volume over time. Cox proportional‐hazards models were used to assess factors associated with mortality. Temporal trends were evaluated with linear regression.ResultsAfter exclusions, 319 patients were analyzed, of whom 5 (1.6%) were DCD. HLTx volume increased from 2013 to 2023 (p < 0.001). One‐ and 5‐year survival following HLTx was 84.0% and 59.5%, respectively. One‐year survival was higher for patients undergoing HLTx at a high‐volume center (88.3% vs. 77.9%; p = 0.012). After risk adjustment, extracorporeal membrane oxygenation support 72 h posttransplant and predischarge dialysis were associated with increased 1‐year mortality (HR = 3.19, 95% CI = 1.86–5.49 and HR = 3.47, 95% CI = 2.17–5.54, respectively) and 5‐year mortality (HR = 2.901, 95% CI = 1.679–5.011 and HR = 3.327, 95% CI = 2.085–5.311, respectively), but HLTx at a high‐volume center was not associated with either.ConclusionsHLTx volume has resurged, with DCD HLTx emerging as a viable procurement strategy. Factors associated with 1‐ and 5‐year survival may be used to guide postoperative management following HLTx.
Total Copper and Labile Bound Copper Fraction as a Selective and Sensitive Tool in the Evaluation of Wilson Disease
Bornhorst, Joshua A. , Bitzer, Anna C, Day, Patrick L. , Wermers, Michelle, Smith, Carin Y. , Pazdernik, Vanessa K, Pelto, Ryan, Sankaran, Banu, Quicquaro, Adam Michael , Jannetto, Paul J. , Smith, Carin Y , Day, Patrick , Bornhorst, Joshua , Pazdernik, Vanessa K

The Journal of Applied Laboratory Medicine | September 3, 2024 | Volume: 9 | Issue: 6 | Pages: 1014-1027

10.1093/jalm/jfae090 | PMID 39225046 Get It

Abstract Background A dual filtration-based method for determination of serum labile bound copper (LBC) and LBC fraction (LBC/total copper) was developed. Reduced total copper, elevated LBC, and elevated LBC fraction have been reported in Wilson disease (WD). Methods To evaluate the diagnostic performance of these markers, samples were obtained from 21 WD treatment-naïve (WD-TN, no WD treatment or &lt;28 days of treatment) patients, 46 WD standard-of-care–treated (WD-SOC) patients, along with 246 patients representing other potential disorders of copper status. These were then compared to 213 reference interval population patients. Results Receiver operating characteristic curves for the reference population vs WD-TN yielded areas under the curve for total copper, LBC, and LBC fraction, of 0.99, 0.81, and 0.98, respectively. Using Youden cutoffs, sensitivity/specificity for WD-TN was 95%/97% for total copper, 71%/85% for LBC, and 95%/94% for LBC fraction. LBC values, but not total copper and LBC fraction, differed substantially between WD-TN and WD-SOC cohorts. We propose a dual model wherein total copper and LBC fraction results must agree to be classified as a “positive” or “negative” result for WD. This correctly classified 19/21 WD-TN patients as positive, and 194/213 reference interval patients as negative. The remaining “indeterminate” patients (representing approximately 9% of the reference and the WD-TN populations) exhibited conflicting total copper and LBC fraction results. When indeterminate results are excluded, this model exhibited apparent 100% sensitivity/specificity. Conclusions Agreement of total serum copper and LBC fraction classification may constitute an effective “rule-in” and “rule-out” assessment for WD-TN patients.
Correction: Stämmler et al. Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C. Diagnostics 2021, 11, 2291
Stämmler, Frank , Grassi, M , Meeusen, Jeffrey W. , Lieske, John C. , Dasari, Surendra , Dubourg, Laurence , Ehrich, J. H. H. , Schiffer, Eric, Grassi, Marcello , Lieske, John C , Lemoine, Sandrine

Diagnostics | September 3, 2024 | Volume: 14 | Issue: 17 | Pages: 1949

10.3390/diagnostics14171949 | PMID 39272782 Get It

In the original publication [...]
Management of resistant and refractory cytomegalovirus infections after transplantation
Pham, Justin H. , Razonable, Raymund R.

Expert Review of Anti-infective Therapy | September 3, 2024 | Volume: 22 | Issue: 10 | Pages: 855-866

10.1080/14787210.2024.2399647 | PMID 39225411 Get It

Molecular Variability in Levodopa Absorption and Clinical Implications for the Management of Parkinson’s Disease
Menezes, Ana Luisa Pedrosa de, Bloem, Bastiaan R., Beckers, Milan , Piat, Capucine , Benarroch, Eduardo E. , Savica, Rodolfo , Pedrosa de Menezes, Ana Luisa, Menezes, Ana Luisa Pedrosa de, Bloem, Bastiaan R.

Journal of Parkinson’s Disease | September 3, 2024 | Volume: 14 | Issue: 7 | Pages: 1353-1368

10.3233/jpd-240036 | PMID 39240647 Get It

Levodopa is the most widely used medication for the symptomatic treatment of Parkinson’s disease and, despite being an “old” drug, is still considered the gold standard for offering symptomatic relief. The pharmacokinetic and pharmacodynamics of levodopa have been studied extensively. Our review explores the molecular mechanisms that affect the absorption of this drug, focusing on the large intra- and interindividual variability of absorption that is commonly encountered in daily clinical practice, and on the interaction with other medications. In addition, we will explore the clinical implications of levodopa absorption variability and address current and future strategies for researchers and clinicians.
Evaluation of Dermatologic Diagnostic Ability on Skin of Colour in Preclinical Medical Students
Ghalambor, Tara , Penner, Scott, Irwin, Chase , Hastings, Karen Taraszka , Greene, Adina , Hastings, K Taraszka

Skin Health and Disease | September 3, 2024 | Volume: 4 | Issue: 6 | Pages: No page available

10.1002/ski2.425 | PMID 39624754 Get It

Abstract Background Various studies have revealed that there is a disproportionately low representation of skin of colour (SOC) in medical school dermatologic curriculum and board study resources. Methods First-year and second-year medical students were emailed an 18-question survey regarding (1) identifying correct diagnoses of dermatologic conditions on either White skin or SOC and (2) their confidence in identifying dermatologic conditions on SOC. Results 15% of the images of dermatologic conditions included in the institutional preclinical curriculum show images of patients with SOC. Regarding overall scores for diagnosing dermatologic diseases, students performed similarly on both the White image survey (61.73%) and SOC image survey (66.20%) with no statistically significant differences between surveys (p = 0.14). Second-year medical students performed better than first-year medical students overall (p = 0.01) and on White skin image survey scores (p = 0.02) but not on people of colour image survey scores (p = 0.09). Students largely agreed that they were more comfortable identifying dermatologic diagnoses on White skin and that their school could benefit from increased SOC dermatological resources. Conclusion The overall low scores for the diagnosis of common skin conditions on both the White image and SOC image survey by first- and second-year students are not surprising given the results of a prior study and support the need for re-exposure to dermatology presentations in all skin types during the preclinical curriculum. The low scores support the need for changes in the pre-clinical dermatology curriculum to improve diagnostic ability. Second-year students performed better at diagnosing dermatologic conditions overall and on White skin compared to SOC at the end of their didactic years, possibly due to an underrepresentation of SOC images in institutional and outside educational resources. Attitudes towards school-specific dermatologic SOC education demonstrated a clear desire amongst students for more exposure to dermatologic conditions in various skin colours throughout the curriculum.
Impact of Desmopressin ON HemaToma EXPANsion in Patients Presenting to the Emergency Department on Antiplatelet Therapy: DON'T EXPAND Study
Rech, Megan A. , Brown, Caitlin S. , Slocum, Giles W. , Aggarwal, Deep, Ayad, Michael, Delibert, Samantha, Flack, Tara , Guerrero, Luis, Howington, Gavin T. , Koul, Uttara, Laub, Jessica , Malik, Atul, Maynard, Kaylee , Naylor, Ryan M. , Newell, Joshua S, Dee, Elizabeth , Sarangarm, Preeyaporn , Sheldrake, Amy K., Shogren, Sophie L , Treu, Ciarra N, Vantine, Paul, Woolum, Jordan A. , Rech, Megan A , Gilbert, Brian W. , George, Benjamin P. , Koul, Uttara, Malik, Atul, Panos, Nicholas , Ray, Lance , Dee, Elizabeth, Faine, Brett

No container title available | September 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4619324/v1 Get It

Abstract Introduction: Current guidelines state the effectiveness of desmopressin to reduce hematoma expansion in antiplatelet-related intracerebral hemorrhage (ICH) is uncertain. This study sought to determine if desmopressin decreased hematoma expansion in ICH patients on antiplatelet agents. Methods: We conducted a multi-center, retrospective propensity-matched cohort study at 11 US emergency departments (ED) that participate in EMPHARM-NET. Adult patients ≥18 years with a primary diagnosis of spontaneous ICH on antiplatelets prior to admission from January 1, 2017 through May 1, 2021 were included. The primary endpoint was good or excellent hemostatic efficacy within the first 24 hours following ICH between patients that did and did not receive desmopressin. Brain imaging was reviewed using 3D-Slicer by blinded expert physicians. Results: Overall, 1408 patients were evaluated for inclusion. A total of 324 patients were included, of which 13.8% (n=45) received desmopressin and 86.1% (n=279) did not. After propensity matching, 35 patients receive desmopressin compared to 140 controls. Baseline hematoma volume (27.6 mL vs. 2.1 mL) and was significantly higher in the desmopressin group. The primary endpoint of good or excellent hemostatic efficacy was similar between groups (74.3% desmopressin group vs. 85% control group, -10.7% [-28.1% to 6.7%]). There was no difference in secondary outcomes. Conclusion: In this multicenter cohort, patients receiving desmopressin had higher baseline intraparenchymal hematoma volume, and did not appear to result in improved hemostatic efficacy relative to the control group. These results suggest against routine administration of desmopressin for antiplatelet-related ICH, though future study in a randomized trial design is necessary.
Trends in adverse effects of medical treatment in Paediatric populations in the United States: A global burden of disease study, 2000–2019
Fujiwara, Shintaro , Leibovitch, Emily , Nishimura, Yoshito , Woo, Russell , Bhagavathula, Akshaya Srikanth , Nishimura, Yoshito , Bhagavathula, Akshaya Srikanth , Harada, Ko , Otsuka, Fumio

Paediatric and Perinatal Epidemiology | September 3, 2024 | Volume: 38 | Issue: 8 | Pages: 692-699

10.1111/ppe.13116 | PMID 39225176 Get It

AbstractBackgroundAdverse effects of medical treatment (AEMT) pose significant risks to paediatric patients. However, the mortality trends associated with AEMT in this population have been unclear.ObjectiveWe aimed to clarify the trends in the incidence, disability‐adjusted life years (DALYs) and mortality rates of AEMT for children in the US from 2000 to 2019.MethodsData were retrieved from the Global Burden of Disease study 2019. We estimated age‐standardized incidence, DALYs and mortality rates of paediatric AEMT per 100,000 children in the US using a Bayesian meta‐regression model. We also analysed incidence, DALYs and mortality in different age groups, and employed Joinpoint regression models to assess the age‐ and sex‐specific trends.ResultsThe number of deaths due to AEMT in children, the number of cases, and DALYs were 105.1, 551,076 and 145,555 in 2019, decreased by 37.5%, 6% and 28% from those in 2000, respectively. Age‐standardized mortality rates decreased across all age groups, while the incidence increased across all age groups with an average annual percentage change (AAPC) of 2.2% in those children <1 year and 4.5% in 5–9 years of age. The increases in DALYs over time was higher in children aged 1–4 years (AAPC: 0.51, 95% CI: 0.47, 0.62) and 5–9 years (AAPC: 0.33, 95% CI: 0.15, 0.50), with the 1–4 year age group being the highest.ConclusionThe study reveals declining AEMT mortality but rising incidence and DALYs, emphasizing a disproportionate burden in <1, 1–4 and 5–9 years. To develop effective mitigation strategies, future research is warranted to identify the causes of increased AEMT in children, especially young males.
Burden of illness and treatment attitudes among participants meeting Rome IV criteria for irritable bowel syndrome: A nationwide survey in the United States
Lacy, Brian E. , Xu, Yanqing , Taylor, Douglas C.A., Kosch, Katherine J., Dobrescu, Rachel, Morlock, Amy, Morlock, Robert , Rooker, Ceciel, Rooker, Ceciel

Neurogastroenterology & Motility | September 3, 2024 | Volume: 36 | Issue: 11 | Pages: No page available

10.1111/nmo.14903 | PMID 39223955 Get It

AbstractBackgroundIrritable bowel syndrome (IBS) is a disorder of gut–brain interaction characterized by abdominal pain and altered bowel habits, with patient‐perceived dissatisfaction of treatment symptom control. We assessed disease burden, satisfaction with medication use, and impact on activities, in participants with IBS with constipation (IBS‐C) and diarrhea (IBS‐D).MethodsThis study assessed data from a large, United States survey of adults querying demographics, comorbid conditions, quality of life, medication use, satisfaction with symptom control, and work productivity. Participants were grouped into the IBS‐C or IBS‐D cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self‐reported.Key ResultsNine hundred and ten participants with IBS‐C and 669 with IBS‐D were matched to controls. The most reported symptoms were abdominal discomfort for IBS‐C and abdominal pain and abdominal discomfort for IBS‐D. Among the IBS‐C and IBS‐D cohorts, 74.2% and 65.9%, respectively, took prescription and/or over‐the‐counter medication for their symptoms. Respondents were more dissatisfied than satisfied with control of their symptoms. Respondents taking prescription medication(s) with or without over‐the‐counter medication(s) reported better symptom control than respondents only taking over‐the‐counter medications (p < 0.001). There was significantly higher mean presenteeism, work productivity loss, and daily activity impairment (p < 0.001 for all) in respondents with IBS compared with controls.Conclusions and InferencesThis study provides insight into respondents' experiences of IBS symptoms, including the impact on daily activity, as well as satisfaction with control of symptoms and prescription and over‐the‐counter medications.